Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by ReCode Therapeutics
ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis
February 21, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in February Conferences
February 20, 2024
From
ReCode Therapeutics
Via
Business Wire
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
February 15, 2024
From
ReCode Therapeutics
Via
Business Wire
Tickers
NTLA
ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia
January 03, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in November Conferences
November 10, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces Closing of Extension to Series B Financing
September 19, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at September Investor Conferences
September 07, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs
July 10, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at Jefferies Healthcare Conference
June 02, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development
April 17, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
March 27, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines
March 21, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia
March 15, 2023
From
ReCode Therapeutics
Via
Business Wire
Recode Therapeutics Expands Leadership Team with Appointment of April Loui as Senior Vice President of Quality and CMC Regulatory Affairs
February 01, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy
January 10, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform
January 09, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Appoints Trisha Millican to Board of Directors
December 01, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at Upcoming Investor Conferences in 2022
November 22, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Establishes Scientific Advisory Board
November 14, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in Upcoming November Investor Conferences
November 02, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in Upcoming October Investor Conferences
September 29, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit
September 22, 2022
From
ReCode Therapeutics
Via
Business Wire
Fierce Biotech Names ReCode Therapeutics as One of its “Fierce 15” Biotech Companies of 2022
September 12, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in Upcoming July Investor Conferences
July 06, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M
June 29, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at Jefferies Healthcare Conference
June 03, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis at the ATS 2022 International Conference
May 18, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference
May 15, 2022
From
ReCode Therapeutics
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.